mm-302
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Mar 1, 2011 (NCT01304797)
Timeline
Indications
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2BINDING AGENT
ERBB2 binding agent
Upon binding of the antibody to receptor protein-tyrosine kinase ERBB2, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the ERBB2 receptor.
- DNA topoisomerase II alphaINHIBITOR
TOP2A inhibitor
Upon binding of the antibody to the receptor protein-tyrosine kinase ERBB2, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the ERBB2 receptor. Once inside the HER2-expressing tumor cells, doxorubicin intercalates into DNA and interferes with DNA topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis.
ERBB2 inhibitor
- DNAINHIBITOR
DNA inhibitor
Upon binding of the antibody to the receptor protein-tyrosine kinase ERBB2, the immunoliposome allows for specific delivery of doxorubicin to tumors overexpressing the ERBB2 receptor. Once inside the HER2-expressing tumor cells, doxorubicin intercalates into DNA and interferes with DNA topoisomerase II activity, thereby inhibiting DNA replication and RNA synthesis.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- doxorubicin
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3833344 ↗
Also known as
- mm-302
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02735798 | Early Phase 1 (Phase 1) | Apr 1, 2016 | University of California, San Francisco |
| NCT02213744 | Phase 2/Phase 3 (Phase 3) | Jul 1, 2014 | Merrimack Pharmaceuticals |
| NCT01304797 | Phase 1 | Mar 1, 2011 | Merrimack Pharmaceuticals |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Merrimack Pharmaceuticals | For profit | 2 | 2 | 2 | 2011 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2016 |